Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation
- PMID: 22641540
- DOI: 10.5603/cj.2012.0043
Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation
Abstract
Upstream therapy is the promising issue in the treatment of atrial fibrillation (AF) especially in patients with arterial hypertension and heart failure. The possible beneficial effects of renin-angiotensin-aldosterone system blockade with ACE-inhibitors and angiotensin receptor antagonists in AF prevention have been demonstrated in experimental and clinical studies. There is growing mass of evidence, from both theoretical and experimental research studies, to suggest that upstream therapy using spironolactone or eplerenone may reduce the deleterious effect of excess aldosterone secretion and further modify the environment of AF including inhibition of atrial muscle fibrosis. It refers to patients with different forms of AF, including chronic AF. Aldosterone antagonists treatment may be a simple and valuable additional option in low-risk, hypertensive and heart failure patients in primary and secondary prevention of refractory paroxysmal and persistent AF.
Similar articles
-
Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation.Br J Pharmacol. 2010 Apr;159(8):1581-3. doi: 10.1111/j.1476-5381.2010.00675.x. Br J Pharmacol. 2010. PMID: 20388187 Free PMC article.
-
Hypertension and ethnic group: eplerenone may have role in hypertension related atrial fibrillation.BMJ. 2006 Apr 22;332(7547):974. doi: 10.1136/bmj.332.7547.974-b. BMJ. 2006. PMID: 16627524 Free PMC article. No abstract available.
-
Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation.Am J Cardiol. 2013 Apr 1;111(7):1012-8. doi: 10.1016/j.amjcard.2012.12.020. Epub 2013 Jan 19. Am J Cardiol. 2013. PMID: 23340033
-
Selective aldosterone blockade with eplerenone in patients with congestive heart failure.Expert Opin Investig Drugs. 2003 Aug;12(8):1423-7. doi: 10.1517/13543784.12.8.1423. Expert Opin Investig Drugs. 2003. PMID: 12882627 Review.
-
Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials.Int J Cardiol. 2013 Apr 30;165(1):17-24. doi: 10.1016/j.ijcard.2012.02.009. Epub 2012 Mar 14. Int J Cardiol. 2013. PMID: 22421406 Review.
Cited by
-
Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study.Clin Res Cardiol. 2015 Jan;104(1):31-7. doi: 10.1007/s00392-014-0754-7. Epub 2014 Aug 19. Clin Res Cardiol. 2015. PMID: 25134923
-
The Dose-Dependent Effects of Spironolactone on TGF-β1 Expression and the Vulnerability to Atrial Fibrillation in Spontaneously Hypertensive Rats.Cardiol Res Pract. 2021 Sep 27;2021:9924381. doi: 10.1155/2021/9924381. eCollection 2021. Cardiol Res Pract. 2021. PMID: 34616570 Free PMC article.
-
Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble.Hypertension. 2017 Apr;69(4):545-550. doi: 10.1161/HYPERTENSIONAHA.116.08956. Hypertension. 2017. PMID: 28264920 Free PMC article. Review. No abstract available.
-
Atrial Myopathy Underlying Atrial Fibrillation.Arrhythm Electrophysiol Rev. 2020 Aug;9(2):61-70. doi: 10.15420/aer.2020.13. Arrhythm Electrophysiol Rev. 2020. PMID: 32983526 Free PMC article. Review.
-
Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure.J Am Heart Assoc. 2017 Jan 10;6(1):e004119. doi: 10.1161/JAHA.116.004119. J Am Heart Assoc. 2017. PMID: 28073769 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
